LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 101–200 of 1,004
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
“Thus, in the case of upregulation, miRNAs represent interesting target molecules for inhibition through miRNA antagonists such as antagomiRs or antimiRs (36, 37).”
MicroRNAs in neuronal function and dysfunction
Im, H.-I., & Kenny, P. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.01.004 · Cited by 399
Integration of microRNA miR-122 in hepatic circadian gene expression
Gatfield, D., Le Martelot, G., Vejnar, C. E., Gerlach, D., Schaad, O., Fleury-Olela, F., Ruskeepää, A.-L., Oresic, M., Esau, C. C., Zdobnov, E. M., et al. (2009) · Genes & Development · doi:10.1101/gad.1781009 · Cited by 393
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
“Furthermore, several animal studies have concluded that modified RNA-based oligonucleotides are specific, stable and non-toxic when delivered intravenously [50,51].”
BackgroundStriatal microRNA controls cocaine intake through CREB signalling
Hollander, J. A., Im, H.-I., Amelio, A. L., Kocerha, J., Bali, P., Lu, Q., Willoughby, D., Wahlestedt, C., Conkright, M. D., & Kenny, P. J. (2010) · Nature · doi:10.1038/nature09202 · Cited by 388
Broderick, J. A., & Zamore, P. D. (2011) · Gene Therapy · doi:10.1038/gt.2011.50 · Cited by 388
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
Toward MicroRNA–Based Therapeutics for Heart Disease: The Sense in Antisense
van Rooij, E., Marshall, W. S., & Olson, E. N. (2008) · Circulation Research · doi:10.1161/circresaha.108.183426 · Cited by 377
Mathé, E. A., Nguyen, G. H., Bowman, E. D., Zhao, Y., Budhu, A., Schetter, A. J., Braun, R., Reimers, M., Kumamoto, K., Hughes, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1467 · Cited by 374
Liu, X., Sempere, L. F., Ouyang, H., Memoli, V. A., Andrew, A. S., Luo, Y., Demidenko, E., Korc, M., Shi, W., Preis, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39566 · Cited by 373
“Notably, in vitro and in vivo reports of LNA-mediated silencing of miRNAs support the use of LNAs for targeting specific miRNAs (39, 40).”
BackgroundSelf-citationInhibiting MicroRNA-192 Ameliorates Renal Fibrosis in Diabetic Nephropathy
Putta, S., Lanting, L., Sun, G., Lawson, G., Kato, M., & Natarajan, R. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050485 · Cited by 368
MicroRNA-132 Potentiates Cholinergic Anti-Inflammatory Signaling by Targeting Acetylcholinesterase
Shaked, I., Meerson, A., Wolf, Y., Avni, R., Greenberg, D., Gilboa-Geffen, A., & Soreq, H. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.019 · Cited by 366
CHAN, Y. C., BANERJEE, J., CHOI, S. Y., & SEN, C. K. (2012) · Microcirculation · doi:10.1111/j.1549-8719.2011.00154.x · Cited by 364
“Acute administration of unconjugated LNA-modified oligonucleotide against miR-122, a miR that regulates cholesterol biosynthesis, effectively down-regulated hepatic miR-122 in African green monkeys, which was accompanied by a decrease in plasma cholesterol in a dose-dependent manner [24].”
BackgroundMiravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
“SPC3649 has been tested in mice (21,22), African green monkeys (22), as well as chimpanzee models of HCV infection (23).”
BackgroundMicroRNAs in Common Human Diseases
Li, Y., & Kowdley, K. V. (2012) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2012.07.005 · Cited by 360
“This miRNA drug demonstrated impressive repression efficacy on miR-122 in mice [105] and in African green monkeys [106], as well as anti-viral efficacy in chimpanzees chronically infected by HCV [74].”
BackgroundStress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice
Patrick, D. M., Montgomery, R. L., Qi, X., Obad, S., Kauppinen, S., Hill, J. A., van Rooij, E., & Olson, E. N. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43604 · Cited by 360
“Therapeutic efficacy of LNAantimiR technology has recently been reported (21, 22).”
BackgroundSelf-citationMicroRNA-regulated pathways associated with endometriosis
Ohlsson Teague, E. M. C., Van der Hoek, K. H., Van der Hoek, M. B., Perry, N., Wagaarachchi, P., Robertson, S. A., Print, C. G., & Hull, L. M. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0387 · Cited by 357
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
“By introducing an extra methylene bridge connecting the 2′-O atom and the 4′-C atom, the ribose moiety of the RNA is “locked” in C3′-endo or C2′-endo conformation, hence the name [137].”
BackgroundMicroRNAs: New Tools for Diagnosis, Prognosis, and Therapy in Hepatocellular Carcinoma?
Giordano, S., & Columbano, A. (2013) · Hepatology · doi:10.1002/hep.26095 · Cited by 354
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 352
Deiuliis, J. A. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.170 · Cited by 349
Modulation of mismatch repair and genomic stability by miR-155
Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., Adair, B., Vannini, I., Fanini, F., Bottoni, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002472107 · Cited by 349
“In these studies, MV4-11 cells were transfected with a sequencespecific locked nucleic acid (LNA) modified oligonucleotide that targets miR-155 knockdown (anti–miR-155; Exiqon), as well as a control LNA anti-miR (30).”
BackgroundTGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3
Wang, B., Hsu, S. H., Majumder, S., Kutay, H., Huang, W., Jacob, S. T., & Ghoshal, K. (2010) · Oncogene · doi:10.1038/onc.2009.468 · Cited by 348
“Similar observation has been made recently in non-human primates (Elmen et al., 2008), further confirming the effectiveness of these small molecules as a novel class of therapeutics for disease-specific miRNAs.”
ResultRNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Causes and Consequences of MicroRNA Dysregulation
Iorio, M. V., & Croce, C. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318250c001 · Cited by 333
Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
“This enthusiasm is buoyed, perhaps in no small part, by the recognition that there are far less miRNAs (predicted to be around 1,000) than mRNAs (~24,000 genes, plus numerous splicing variants) and also by the recent reports of successful and well-tolerated use of anti-miRs in animal studies (Esau et al., 2006; Elmen…”
BackgroundYamada, H., Suzuki, K., Ichino, N., Ando, Y., Sawada, A., Osakabe, K., Sugimoto, K., Ohashi, K., Teradaira, R., Inoue, T., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.021 · Cited by 327
Song, S. J., Ito, K., Ala, U., Kats, L., Webster, K., Sun, S. M., Jongen-Lavrencic, M., Manova-Todorova, K., Teruya-Feldstein, J., Avigan, D. E., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.06.003 · Cited by 326
“Finally, since the technology to inhibit miRNAs for therapy is rapidly evolving (Elmén et al., 2008; Stenvang et al., 2008), this will impact treatment options for a range of diseases and disorders in the years to come.”
BackgroundSuárez, Y., Wang, C., Manes, T. D., & Pober, J. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902369 · Cited by 320
Sonkoly, E., Janson, P., Majuri, M.-L., Savinko, T., Fyhrquist, N., Eidsmo, L., Xu, N., Meisgen, F., Wei, T., Bradley, M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.045 · Cited by 317
Self-citationInhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Hinkel, R., Penzkofer, D., Zühlke, S., Fischer, A., Husada, W., Xu, Q.-F., Baloch, E., van Rooij, E., Zeiher, A. M., Kupatt, C., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001904 · Cited by 317
The role of microRNAs in endometriosis and associated reproductive conditions
Ohlsson Teague, E. M. C., Print, C. G., & Hull, M. L. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp034 · Cited by 309
MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality
Gramantieri, L., Fornari, F., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Bolondi, L., & Negrini, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0092 · Cited by 308
Fernández-Hernando, C., Suárez, Y., Rayner, K. J., & Moore, K. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283428d9d · Cited by 308
Regulation of Hepatitis C Virus Translation and Infectious Virus Production by the MicroRNA miR-122
Jangra, R. K., Yi, M., & Lemon, S. M. (2010) · Journal of Virology · doi:10.1128/jvi.00417-10 · Cited by 306
“It is a key regulator of lipid and cholesterol biosynthesis in the liver (4, 5, 20).”
BackgroundSarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M. H., & Filipowicz, W. (2009) · Nature Medicine · doi:10.1038/nm.1902 · Cited by 304
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
“Either cholesterol-bound oligonucleotides (antagomirs), or LNA-modified oligonucleotides (LNA anti-miR) were also found to be effective in stably suppressing miRNA activity in the in vivo condition [156, 157].”
BackgroundMicroRNAs in Heart Failure: From Biomarker to Target for Therapy
Vegter, E. L., van der Meer, P., de Windt, L. J., Pinto, Y. M., & Voors, A. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.495 · Cited by 303
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
“Our strategy for inhibiting miR-122 in the mouse liver turned out to be successful: a 16-mer LNA-modified antimiR oligonucleotide reproduced the low cholesterol phenotype upon systemic delivery in mice (Elmén et al., 2008a).”
BackgroundMethodInfluentialSelf-citationMicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion
Maegdefessel, L., Azuma, J., Toh, R., Deng, A., Merk, D. R., Raiesdana, A., Leeper, N. J., Raaz, U., Schoelmerich, A. M., McConnell, M. V., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003441 · Cited by 301
Diabetes mellitus, a microRNA-related disease?
Guay, C., Roggli, E., Nesca, V., Jacovetti, C., & Regazzi, R. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.009 · Cited by 300
MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment
Quiat, D., & Olson, E. N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62876 · Cited by 300
“…primarily as antiviral therapy against hepatitis C virus infection, have similarly revealed the beneficial effects of anti–miR-122 treatment on lipid profiles in primates and established proof of efficacy and minimal toxicity of LNA-modified anti-miR therapeutics in a preclinical model (40, 41).”
Control of metastatic progression by microRNA regulatory networks
Pencheva, N., & Tavazoie, S. F. (2013) · Nature Cell Biology · doi:10.1038/ncb2769 · Cited by 295
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction
Kocerha, J., Faghihi, M. A., Lopez-Toledano, M. A., Huang, J., Ramsey, A. J., Caron, M. G., Sales, N., Willoughby, D., Elmen, J., Hansen, H. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805854106 · Cited by 295
“, designed to hybridize with miRNAs) they have been shown to potently antagonize the biological activity of miRNAs in rodents (38) and nonhuman primates (39).”
BackgroundSelf-citationTorella, D., Iaconetti, C., Catalucci, D., Ellison, G. M., Leone, A., Waring, C. D., Bochicchio, A., Vicinanza, C., Aquila, I., Curcio, A., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.240150 · Cited by 293
microRNAs: Master Regulators as Potential Therapeutics in Cancer
Garofalo, M., & Croce, C. M. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100517 · Cited by 291
Epigenetic principles and mechanisms underlying nervous system functions in health and disease
MEHLER, M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.10.001 · Cited by 291
“…are increasing being applied to combat complex and aberrant arrays of epigenetic targets such as multiple ncRNAs, including miRNAs, RNA/DNA editing enzymes and nucleosome and chromatin remodeling complexes (Akhtar and Benter, 2007; Bhindi et al., 2007; Elmen et al., 2008; Sigalotti et al., 2007).”
BackgroundSilencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis
Murugaiyan, G., Beynon, V., Mittal, A., Joller, N., & Weiner, H. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003952 · Cited by 289
“Therapeutic efficacy of LNA-modified oligonucleotide (LNA–anti-miR) technology has recently been reported (21, 22).”
microRNAs in the Regulation of Adipogenesis and Obesity
A. McGregor, R., & S. Choi, M. (2011) · Current Molecular Medicine · doi:10.2174/156652411795677990 · Cited by 287
Scioli, M. G., Storti, G., D’Amico, F., Rodríguez Guzmán, R., Centofanti, F., Doldo, E., Céspedes Miranda, E. M., & Orlandi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061995 · Cited by 281
Wang, X. W., Heegaard, N. H. H., & Ørum, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.007 · Cited by 280
Li, J. J., Bickel, P. J., & Biggin, M. D. (2014) · PeerJ · doi:10.7717/peerj.270 · Cited by 279
“2008; Elmen et al. 2008; Gennarino et al. 2012; Guo et al. 2010; Hobert 2008; Krutzfeldt et 36 al.”
BackgroundCampbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
MicroRNAs and cancer: past, present, and potential future
Nelson, K. M., & Weiss, G. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0586 · Cited by 279
“Delivery systems such as locked nucleic acid increase the stability of miRNAs for in vivo application (46) and may be promising as cancer therapy.”
BackgroundAnti-miRNA oligonucleotides: A comprehensive guide for design
Lima, J. F., Cerqueira, L., Figueiredo, C., Oliveira, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 276
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
The prognostic and functional role of microRNAs in acute myeloid leukemia
Marcucci, G., Mrózek, K., Radmacher, M. D., Garzon, R., & Bloomfield, C. D. (2011) · Blood · doi:10.1182/blood-2010-09-191312 · Cited by 270
van Solingen, C., Seghers, L., Bijkerk, R., Duijs, J. M. G. J., Roeten, M. K., van Oeveren‐Rietdijk, A. M., Baelde, H. J., Monge, M., Vos, J. B., de Boer, H. C., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00613.x · Cited by 269
Targeting Age-Related Pathways in Heart Failure
Li, H., Hastings, M. H., Rhee, J., Trager, L. E., Roh, J. D., & Rosenzweig, A. (2020) · Circulation Research · doi:10.1161/circresaha.119.315889 · Cited by 266
Luo, X., Pan, Z., Shan, H., Xiao, J., Sun, X., Wang, N., Lin, H., Xiao, L., Maguy, A., Qi, X.-Y., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62185 · Cited by 266
Macrophages, Chronic Inflammation, and Insulin Resistance
Li, H., Meng, Y., He, S., Tan, X., Zhang, Y., Zhang, X., Wang, L., & Zheng, W. (2022) · Cells · doi:10.3390/cells11193001 · Cited by 264
“Presently, there are two main therapeutic methods: miRNA mimics to restore the miRNAs downregulated in diabetes, miRNA mimics that are synthetic RNA duplexes, liposomes, and adeno-associated virus preparations designed to package miRNAs [238,239]; the other method is to inhibit miRNAs that express significantly higher…”
MethodGAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
“The inhibition of miRNA activity can be readily achieved by the use of miRNA inhibitors and oligomers, including RNA, DNA and DNA analogues (miRNA antisense therapy) (45-47), small molecule inhibitors, locked nucleic acids (LNAs) (48-53), peptide nucleic acids (PNAs) (54-57), morpholinos (58-60), miRNA sponges (61-67)…”
BackgroundNutrition, Epigenetics, and Metabolic Syndrome
Wang, J., Wu, Z., Li, D., Li, N., Dindot, S. V., Satterfield, M. C., Bazer, F. W., & Wu, G. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4381 · Cited by 261
Young, D. D., Connelly, C. M., Grohmann, C., & Deiters, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910275u · Cited by 260
MicroRNAs in Metabolic Disease
Fernández-Hernando, C., Ramírez, C. M., Goedeke, L., & Suárez, Y. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300144 · Cited by 257
MicroRNA regulation of autophagy
Frankel, L. B., & Lund, A. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs266 · Cited by 256
MicroRNA in ischemic stroke etiology and pathology
Rink, C., & Khanna, S. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2010 · Cited by 255
“Systemic administration of a phosphate-buffered solution formulated LNA-antimiR for miR-122 demonstrated potent antagonism of liver-expressed miR-122 in nonhuman primates (16).”
BackgroundWilleit, P., Skroblin, P., Moschen, A. R., Yin, X., Kaudewitz, D., Zampetaki, A., Barwari, T., Whitehead, M., Ramírez, C. M., Goedeke, L., et al. (2017) · Diabetes · doi:10.2337/db16-0731 · Cited by 255
“Inhibition of miR-122 in mice (4,5) and nonhuman primates (6,7) induces fatty acid oxidation, reduces lipid synthesis, and thereby leads to lower levels of total cholesterol.”
BackgroundThe role of microRNAs in colorectal cancer
Schetter, A. J., Okayama, H., & Harris, C. C. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b78f · Cited by 252
MiRNAs as biomarkers and therapeutic targets in cancer
Heneghan, H. M., Miller, N., & Kerin, M. J. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.05.010 · Cited by 252
Non-coding RNAs in Cardiac Remodeling and Heart Failure
Kumarswamy, R., & Thum, T. (2013) · Circulation Research · doi:10.1161/circresaha.113.300226 · Cited by 249
The emerging roles of microRNAs in CNS injuries
Bhalala, O. G., Srikanth, M., & Kessler, J. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.67 · Cited by 248
Therapeutic targeting of non-coding RNAs in cancer
Slaby, O., Laga, R., & Sedlacek, O. (2017) · Biochemical Journal · doi:10.1042/bcj20170079 · Cited by 248
The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice
Castoldi, M., Vujic Spasic, M., Altamura, S., Elmén, J., Lindow, M., Kiss, J., Stolte, J., Sparla, R., D’Alessandro, L. A., Klingmüller, U., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44883 · Cited by 247
Self-citationThe carnitine system and cancer metabolic plasticity
Melone, M. A. B., Valentino, A., Margarucci, S., Galderisi, U., Giordano, A., & Peluso, G. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0313-7 · Cited by 246
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
“to monkeys enter the cytoplasm in hepatocytes, form functional heteroduplexes with microRNA, and can regulate cholesterol metabolism (41).”
BackgroundDelivery of therapeutic oligonucleotides with cell penetrating peptides
Boisguérin, P., Deshayes, S., Gait, M. J., O'Donovan, L., Godfrey, C., Betts, C. A., Wood, M. J. A., & Lebleu, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.008 · Cited by 245
MicroRNAs in Vascular and Metabolic Disease
Zampetaki, A., & Mayr, M. (2012) · Circulation Research · doi:10.1161/circresaha.111.247445 · Cited by 244
Bukh, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.035 · Cited by 244
An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., Di Lauro, R., & Verde, P. (2009) · Oncogene · doi:10.1038/onc.2008.370 · Cited by 242
“Importantly, miRNAs exhibit high therapeutic potential, as shown by the in vivo application of chemically modified miRNA inhibitors (antagomirs), for treatment of animal models of human disease (Elmen et al., 2008).”
BackgroundRamirez, C. M., Dávalos, A., Goedeke, L., Salerno, A. G., Warrier, N., Cirera-Salinas, D., Suárez, Y., & Fernández-Hernando, C. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.232066 · Cited by 242
Proinflammatory Role for let-7 MicroRNAS in Experimental Asthma
Polikepahad, S., Knight, J. M., Naghavi, A. O., Oplt, T., Creighton, C. J., Shaw, C., Benham, A. L., Kim, J., Soibam, B., Harris, R. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145698 · Cited by 242
miRNAs and NAFLD: from pathophysiology to therapy
Gjorgjieva, M., Sobolewski, C., Dolicka, D., Correia de Sousa, M., & Foti, M. (2019) · Gut · doi:10.1136/gutjnl-2018-318146 · Cited by 241
Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications
Veedu, R. N., & Wengel, J. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900343 · Cited by 240
RNA therapeutics: RNAi and antisense mechanisms and clinical applications
Chery, J. (2016) · Postdoc Journal · doi:10.14304/surya.jpr.v4n7.5 · Cited by 240
MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis
Murugaiyan, G., da Cunha, A. P., Ajay, A. K., Joller, N., Garo, L. P., Kumaradevan, S., Yosef, N., Vaidya, V. S., & Weiner, H. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74347 · Cited by 239
MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels
Goedeke, L., Rotllan, N., Canfrán-Duque, A., Aranda, J. F., Ramírez, C. M., Araldi, E., Lin, C.-S., Anderson, N. N., Wagschal, A., de Cabo, R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3949 · Cited by 238
“…demonstrate the critical role of miRNAs in regulating cellular cholesterol efflux and HDL biogenesis 19–24 , while the liver-restricted miR-122 has been linked to the regulation of cholesterol and fatty acid synthesis through loss-of-function experiments in mice and non-human primates 25–27 .”
Kato, M., Arce, L., Wang, M., Putta, S., Lanting, L., & Natarajan, R. (2011) · Kidney International · doi:10.1038/ki.2011.43 · Cited by 238
“Their widespread and distinct expression patterns under normal and disease states make miRNAs attractive molecular therapeutic targets for human diseases, especially because of the recent advances in the development of chemically modified inhibitors of miRNAs like antagomirs(20) and locked nucleic acid (LNA) antimiRs.…”
MicroRNAs and cancer—new paradigms in molecular oncology
Negrini, M., Nicoloso, M. S., & Calin, G. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.03.002 · Cited by 236
Jayawardena, T. M., Finch, E. A., Zhang, L., Zhang, H., Hodgkinson, C. P., Pratt, R. E., Rosenberg, P. B., Mirotsou, M., & Dzau, V. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.304510 · Cited by 235
Liu, Y., Taylor, N. E., Lu, L., Usa, K., Cowley, A. W., Ferreri, N. R., Yeo, N. C., & Liang, M. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.144428 · Cited by 235
Thakral, S., & Ghoshal, K. (2015) · Current Gene Therapy · doi:10.2174/1566523214666141224095610 · Cited by 235
“However, decreases in both potentially atherogenic LDL-cholesterol and cardio-protective HDLcholesterol in rodents [16] and primates [35] suggest that implementing anti-miR-122 therapy may not be optimal for cardiovascular risk management in human patients.”
BackgroundMethodThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Predicting free energy changes using structural ensembles
Benedix, A., Becker, C. M., de Groot, B. L., Caflisch, A., & Böckmann, R. A. (2009) · Nature Methods · doi:10.1038/nmeth0109-3 · Cited by 234
MicroRNAs in cancer — from research to therapy
Cho, W. C. S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.003 · Cited by 233
Asl, E. R., Amini, M., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 231
Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
Yang, N., Ekanem, N. R., Sakyi, C. A., & Ray, S. D. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.029 · Cited by 230
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.